BioSpace News Archive

Cullinan Management Inc. and Gracell Biotechnologies, two biotech IPOs that focus on cancer research and developing new oncology treatments, set their terms and are set to start trading on Friday January, 8.

Biotech growth in China continued at a rapid pace in 2020, despite COVID-19, which emerged from that country to become a global pandemic. Opportunities in China remain good and are expected to continue.

Company will need to provide a new assay to satisfy FDA before commencing Phase I trials.

Blacksmith Medicines announced on Friday it had secured a multimillion dollar seed funding deal from Eli Lilly and has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets.

Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA

Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Dr. Ramona Doyle as its Chief Medical Officer

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference. The fireside chat will be available beginning at 6:00 a.m. ET Monday, January 11, 2021 on the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra

Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23 rd Annual Needham Growth Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 15, 2021, at 1:15 p.m. Eastern Time. A live webcast of the presentati

- Blue Note Therapeutics is developing prescription digital therapeutics specifically designed to treat cancer-related anxiety, depression, and fear of recurrence - Blue Note’s lead product received Breakthrough Device Designation from the FDA in June 2020